Skip to main content
OpenTrials
Completed

NCT Number: NCT01880424

A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

This clinical trial is an international, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial comparing one dose of linaclotide to placebo. Approximately 800 patients with a diagnosis of IBS-C (modified Rome III criteria) will be randomized at up to 60 trial centers in China, Australia, and New Zealand.

The trial will consist of up to 21 days of screening, 14 to 21 days of pre-treatment, 12 weeks of double-blind treatment, and 2 weeks of follow-up. At the end of the Pre-treatment Period, patients meeting the entry criteria for this trial will be randomized to one of two double-blind treatment groups: 290 ug linaclotide, or placebo (1:1).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Irritable Bowel Syndrome With Constipation (IBS-C)

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Research Site, Adelaide, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient has signed an Informed Consent Form(ICF).
  • Patient Must not be pregnant or breastfeeding and agree to use birth control
  • Patient meets the colonoscopy requirements defined by the American Gastroenterological Association guidelines and no clinically-significant laboratory or physical examination findings;
  • Patient meets protocol-defined criteria for Irritable Bowel Syndrome with Constipation(IBS-C), including stool frequency, straining, stool consistency, abdominal pain, and abdominal discomfort criteria
  • Patient meets protocol-defined eDiary completion Compliance and agrees to refrain from making any new, major life-style changes that may affect IBS-C symptoms

Exclusion criteria

  • Recent history of mushy or watery stools
  • Various medical conditions, medical histories, or family medical histories that would not make the patient a good candidate for the study
  • Patient currently has both unexplained and clinically significant alarm symptoms or systemic signs of infection or colitis.
  • Surgery to the gastrointestinal tract
  • Usage of prohibited medications

Treatment and study plan

Placebo

Drug

matching Placebo Capsules, Oral, once daily

Linaclotide

Drug

Linaclotide 290 ug Capsules, Oral, once daily

Primary outcomes

  1. 12-week Abdominal Pain/Abdominal Discomfort Weekly Responder

    Time frame: Baseline and Weeks 1-12 during the Treatment Period

    A 12-week Abdominal Pain/Abdominal Discomfort Responder is a patient who meets the Abdominal Pain/Abdominal Discomfort Weekly Responder criteria (i.e., an improvement of ≥30% from baseline in either the mean abdominal pain score or mean abdominal discomfort score for that week, with neither score worsening from baseline for that week) for at least 6 out of the 12 weeks of the Treatment Period.

    Abdominal pain at its worst (in the last 24 hours) was assessed daily by patients on an 11-point numerical rating scale (NRS) where 0 represents no abdominal pain and 10 represents very severe abdominal pain.

    Abdominal discomfort (in the last 24 hours) was assessed daily by patients on an 11-point NRS where 0 represents no abdominal discomfort and 10 represents very severe abdominal discomfort.

  2. 12-week Irritable Bowel Syndrome (IBS) Degree of Relief Responder

    Time frame: Baseline and Weeks 1-12 during the Treatment Period

    A 12-week IBS Degree of Relief Responder is a patient who meets the IBS Degree of Relief Weekly Responder criteria (i.e., response to the degree of relief of IBS symptoms question for that week was "Considerably relieved" or "Completely relieved") for at least 6 out of the 12 weeks of the Treatment Period.

    Degree of relief of IBS symptoms (in the last 7 days) was assessed weekly by patients on a 7-point balanced ordinal scale where 1 = Completely relieved, 4 = Unchanged, and 7 = As bad as I can imagine.

Secondary outcomes

  1. Change From Baseline in 12-week Complete Spontaneous Bowel Movement Frequency Rate

    Time frame: Baseline and 12-week Treatment Period

    The change from baseline in 12-week CSBM frequency (i.e., average weekly CSBM frequency over the 12 weeks of the Treatment Period).

    A spontaneous bowel movement (SBM) is defined as a bowel movement without laxative use in the preceding 24 hours. A CSBM is defined as an SBM that is associated with a sense of complete evacuation.

  2. Change From Baseline in 12-week Spontaneous Bowel Movement Frequency Rate

    Time frame: Baseline and 12-week Treatment Period

    The change from baseline in 12-week SBM frequency (i.e., average weekly SBM frequency over the 12 weeks of the Treatment Period).

    SBM is defined as a bowel movement without laxative use in the preceding 24 hours.

  3. Change From Baseline in 12-week Stool Consistency

    Time frame: Baseline and 12-week Treatment Period

    The change from baseline in 12-week stool consistency (i.e., the average of the non-missing Bristol Stool Form Scale [BSFS] score from the SBMs occurring during the 12-week Treatment Period).

    Consistency of each bowel movement was assessed daily by patients using the 7-point BSFS (1=Separate hard lumps like nuts [difficult to pass] to 7=Watery, no solid pieces [entirely liquid]).

  4. Change From Baseline in 12-week Severity of Straining

    Time frame: Baseline and 12-week Treatment Period

    The change from baseline in 12-week severity of straining (i.e., the average of the non-missing straining scores from the SBMs occurring during the 12-week Treatment Period).

    Severity of straining was assessed daily by patients on a 5-point ordinal scale (1=Not at all to 5=An extreme amount).

  5. Change From Baseline in 12-week Abdominal Bloating

    Time frame: Baseline and 12-week Treatment Period

    The change from baseline in 12-week abdominal bloating (i.e., the average of the non-missing daily abdominal bloating scores reported during the 12-week Treatment Period).

    Abdominal bloating (in the last 24 hours) was assessed daily by patients on an 11-point NRS where 0 represents no abdominal bloating and 10 represents very severe abdominal bloating.

  6. Change From Baseline in 12-week Abdominal Pain

    Time frame: Baseline and 12-week Treatment Period

    The change from baseline in 12-week abdominal pain (i.e., the average of the non-missing daily abdominal pain scores reported during the 12-week Treatment Period).

    Abdominal pain at its worst (in the last 24 hours) was assessed daily by patients on an 11-point NRS where 0 represents no abdominal pain and 10 represents very severe abdominal pain.

  7. Change From Baseline in 12-week Abdominal Discomfort

    Time frame: Baseline and 12-week Treatment Period

    The change from baseline in 12-week abdominal discomfort (i.e., the average of the non-missing daily abdominal discomfort scores reported during the 12-week Treatment Period).

    Abdominal discomfort (in the last 24 hours) was assessed daily by patients on an 11-point NRS where 0 represents no abdominal discomfort and 10 represents very severe abdominal discomfort.

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Collaborators

  • Ironwood Pharmaceuticals, Inc.

Registry information

Acronym: D5630C00001

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Jun 19, 2013
Registry last updated
Sep 27, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.